Cardiovascular Disease

Cardiovascular Disease

Cardiovascular
Disease

Sim Centers

Program Overview

FAMILIAL HYPERCHOLESTEROLEMIA: Making Sense of Disease Mechanisms, Patient Characteristics, and Targeted Treatments
Read More

Christie M. Ballantyne, MD, FACP, FACC

Chief of Cardiology
Chief of Cardiovascular Research
Professor of Medicine
Baylor College of Medicine
Houston, TX

Christie M. Ballantyne, MD is an internationally-renowned expert on lipids, atherosclerosis and heart disease prevention. His research interest in the prevention of heart disease has led him to become an established investigator for the AHA and to receive continuous funding from the NIH since in 1988 in basic research of leukocyte-endothelial interactions, translational research in biomarkers and clinical trials.

Read more »
His many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012 he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Christie as one of “The World’s Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017-2020 in the top 1% of researchers most cited. In 2019, Dr. Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for risk prediction of CV and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids.

With over 800 publications in the area of atherosclerosis, lipids and inflammation, Christie also serves on the Editorial Board for Circulation. Christie is the Chief of Cardiology and the Chief of Cardiovascular Research at Baylor College of Medicine. He is currently the Director for Cardiometabolic Disease Prevention at Baylor College of Medicine.

He received his MD from Baylor College of Medicine with internal medicine residency at The University of Texas Southwestern Medical School and cardiology fellowship at Baylor College of Medicine and an AHA fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.

« Read less

Amy E. Levenson, MD

Assistant Professor of Pediatrics
Division of Pediatric Endocrinology
University of North Carolina School of Medicine
Chapel Hill, NC

Amy E. Levenson, MD, is a Pediatric Oncology Specialist in Chapel Hill, North Carolina, and has over 14 years’ experience in the medical field. She graduated from Drexel University College of Medicine in 2008. Dr. Levenson is affiliated with Boston Children’s Hospital.

Sarah de Ferranti, MD, MPH

Associate Professor of Pediatrics
Director of the Preventive Cardiology Clinic and Division Chief, Outpatient Cardiology
Boston Children’s Hospital
Harvard Medical School
Boston, MA

Sarah de Ferranti, MD, MPH is a pediatric cardiologist in Boston, Massachusetts and is affiliated with Boston Children’s Hospital. She received her medical degree from Tufts University School of Medicine and has been in practice for more than 20 years.

Linda C. Hemphill, MD

Instructor in Medicine
Harvard Medical School
Director of the LDL Apheresis Unit/Massachusetts General Hospital
Boston, MA

Linda C. Hemphill, MD is Instructor in Medicine at Harvard Medical School and Director of the LDL Apheresis Unit at the Massachusetts General Hospital. Dr. Hemphill is an active clinical consultant in lipid management including high LDL cholesterol, high triglycerides, low HDL cholesterol, combined hyperlipidemia, elevated Lp(a) and metabolic syndrome.

Read more »
Dr. Hemphill is a Fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology as well as a Fellow of the American College of Cardiology and Fellow of the National Lipid Association. She is on the editorial board of the Journal of Clinical Lipidology.  She has published on familial hypercholesterolemia and atherosclerosis regression.
« Read less

To Earn CME Credits for this activity, please click below.

Familial Hypercholesterolemia: Cardiologists/Lipidologists

Click to Enter Program

Familial Hypercholesterolemia: Pediatricians

Click to Enter Program

Familial Hypercholesterolemia: Infusion Center

Click to Enter Program

Familial Hypercholesterolemia: Pediatric Cardiologists

Click to Enter Program
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.

Scroll to Top

FAMILIAL HYPERCHOLESTEROLEMIA: Making Sense of Disease Mechanisms, Patient Characteristics, and Targeted Treatments

FACULTY

Christie M. Ballantyne, MD, FACP, FACC
Chief of Cardiology
Chief of Cardiovascular Research
Professor of Medicine
Baylor College of Medicine
Houston, TX

Amy E. Levenson, MD
Assistant Professor of Pediatrics
Division of Pediatric Endocrinology
University of North Carolina School of Medicine
Chapel Hill, N

Sarah D. de Ferranti, MD, MPH
Associate Professor of Pediatrics
Director of the Preventive Cardiology Clinic and Division Chief, Outpatient Cardiology
Boston Children’s Hospital
Harvard Medical Schoo
Boston, MA

Linda C. Hemphill, MD
Instructor in Medicine
Harvard Medical School
Director of the LDL Apheresis Unit/Massachusetts General Hospital
Boston, MA

LEARNING OBJECTIVES

  • Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
  • Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
    with FH
  • Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

TARGET AUDIENCE

This activity is intended for lipidologists, cardiologists, and other healthcare professionals involved in the management of patients with familial hypercholesterolemia (FH).

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with familial hypercholesterolemia. Credits: 1.0 ANCC Contact Hour

ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Faculty MemberDisclosures
Christie M. Ballantyne, MD

Grant/Research Support: Abbott Diagnostic, Akcea Therapeutics, Amgen, Arrowhead, Esperion Therapeutics, Ionis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, and ADA.

Consultant: 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic and Sanofi-Synthélabo.

Amy E. Levenson, MDDr. Levenson reports that she has no actual or potential conflict of interests in relation to this program/presentation.
Sarah D. de Ferranti, MDRoyalties: UpToDate, Inc.
Linda C. Hemphill, MDDr. Hemphill reports that she has no actual or potential conflict of interests in relation to this program/presentation.

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN

Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.

Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.

Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.

Chris Drury, MA, MS, MBA, Scientific and Medical Services for Med Learning Group has nothing to disclose.

Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.

Amanda Jenkins, Program Manager for Med Learning Group has nothing to disclose.

Natalie Smith, Program Coordinator for Med Learning Group has nothing to disclose.

Aimee Meissner, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete and submit the evaluation form to Med Learning Group.

You will receive your certificate after the enduring activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected]

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Home
Clinical Toolkit
Pathophysiology
Diagnosis and Associated Comorbidities
Hypercholesterolemia Management
Current and Emerging Treatments
Reading and Resources
Patient Toolkit
What is Hypercholesterolemia?
Living with Hypercholesterolemia
FAQ
Resources
Can We Talk?
Patient Journey
Upcoming Activities
CME Activities
Poster Portal
Animations
About Us
Diagnosis Referral Treatment Tool
Contact

VR Cobra glasses